Triple
T5981226
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Elan Pharmaceuticals |
E133121
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object | Tysabri |
E24936
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Tysabri | Statement: [Elan Pharmaceuticals, developed, Tysabri]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tysabri Context triple: [Elan Pharmaceuticals, developed, Tysabri]
-
A.
Tysabri
chosen
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
C.
fingolimod
Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
-
D.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0086f45e8819098f73dd16d45ec9d |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04a67c3248190ba35a7121eb49672 |
completed | March 22, 2026, 8 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c0e42174a88190b8b40cbc7815911f |
completed | March 23, 2026, 6:56 a.m. |
Created at: March 22, 2026, 4:04 p.m.